Platinum Industries Ltd

Exclusive India S/P with CAREGEN

• Rivadu Lifesciences, subsidiary of Platinum Industries, entered an exclusive Indian Sale/Purchase agreement with CAREGEN on 28 Sep 2026.
• The agreement covers CAREGEN's health functional food finished products marketed under the brand 'KorgluƟde'.
• Exclusive partnership for the Indian Territory with potential for manufacturing in India.
• No related-party relationship or arm's length concerns identified in the disclosure.
• Regulation 30 SEBI LODR disclosure filed; Annexure A provides details.

Platinum Industries Limited: Trading Window will remain closed from Thursday, October 01, 2026 till the expiry of 48 hours after the declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ending on September 30, 2026 are approved by the Board of Directors.

AGM details

• AGM held on 24 September 2026 with remote and venue e-voting.
• Shareholders attended via video conferencing; eight resolutions were put to vote.

Resolutions and outcomes

• Resolution 1 (Ordinary): Adoption of standalone financial statements — passed.
• Resolution 2 (Ordinary): Adoption of consolidated financial statements — passed.
• Resolution 3 (Ordinary): Reappointment of Anup Singh — passed.
• Resolution 4 (Ordinary): Ratification of cost auditor remuneration — passed.
• Resolution 5 (Special): Grant of loan to Platinum Oleo Chemicals Private Limited — passed.
• Resolution 6 (Special): Grant of loan to Rivadu Lifesciences Private Limited — not passed.
• Resolution 7 (Ordinary): Material related party transaction with Platinum Stabilizers Egypt LLC — passed.
• Resolution 8 (Ordinary): Material related party transaction with Platinum Oleo Chemicals Private Limited — passed.

Dividend

• No dividend proposal or declaration disclosed.

Director changes

• Director Anup Singh to be reappointed; retires by rotation.

Auditors and remuneration

• Cost auditor remuneration for 2026-27 ratified.

Material related party transactions

• RPT with Platinum Stabilizers Egypt LLC approved.
• RPT with Platinum Oleo Chemicals Private Limited approved.

Meeting Details

• Plant visit for investors/analysts scheduled on Tuesday, 29 September 2026, Palghar, Maharashtra.

Participants

• Company Secretary and Compliance Officer to represent the company.

Purpose

• Investor/analyst interaction; discussions to rely on publicly available information.

AGM details

• Date and time: 24 September 2026 at 11:00 IST via VC/OAVM.
• Mode: Video Conference/OAVM.
• Quorum: 41 members attended via VC/OAVM.
• Meeting duration: 11:00–11:30 IST.

Key resolutions

• Adopt standalone financial statements for FY2026; ordinary.
• Adopt consolidated financial statements for FY2026; ordinary.
• Re-appoint Anup Singh by rotation; ordinary.
• Ratify cost auditor remuneration for FY2026-27; ordinary.
• Grant loan/ICD to Platinum Oleo Chemicals Pvt Ltd (subsidiary); special.
• Grant loan/ICD to Rivadu Lifesciences Pvt Ltd (subsidiary); special.
• Material related party transaction with Platinum Stabilizers Egypt LLC; ordinary.
• Material related party transaction with Platinum Oleo Chemicals Pvt Ltd; ordinary.

Voting results

• Voting results not disclosed in the filing; to be declared within two working days.

Director changes

• Anup Singh to be re-appointed by rotation as Director.

Auditors

• Remuneration of Cost Auditor for FY2026-27 ratified.

Related party transactions

• Material RPTs include loans to subsidiaries and other related party transactions; values not disclosed.

AGM details

• 6th AGM on 24 September 2026 at 11:00 IST via VC/OAVM.
• Notice and Annual Report FY 2025-26 sent to shareholders with registered emails.
• E-voting window opens 21 September 2026 at 09:00 IST and closes 23 September 2026 at 17:00 IST.
• E-voting cut-off date set for 17 September 2026.
• AR and AGM Notice available on BSE, NSE, and Platinum website; Bigshare portal.

Shareholder updates and accessibility

• Shareholders without registered emails should update email and KYC with their DP or RTA.
• RTA for updates: Bigshare Services Pvt. Ltd. provides assistance.
• Notice and Annual Report accessible via Platinum Industries website under Investor Relations.

FY26 Financial performance

• Consolidated revenue from operations: ₹4,504.41m, up 14.8% YoY.
• PAT: ₹512.30m; PAT margin 11.37%.
• EBITDA ₹598.50m; EBITDA margin 13.3%.
• Standalone revenue ₹4,343.60m; growth 33.7%.
• Debt-to-equity ratio 0.01; balance sheet remains near debt-free.
• Dividend for FY26 not declared.
• IPO proceeds ₹2,118.29m; unutilised ₹610.42m as of 31 Mar 2026.
• Cash flow: operating ₹10.96m; investing ₹73.32m; financing outflow ₹26.54m.
• Consolidated net worth attributable to owners ₹4,430.57m.
• New Rivadu Lifesciences subsidiary formed 18 Mar 2026.

Capex & capacity expansion

• Palghar Unit II commissioned May 21, 2026; adds ~60,000 MT capacity.
• Egypt 60,000 MTPA facility; commissioning FY27; freight costs cut up to 90%.
• Pilot plant to accelerate formulation validation.
• FY26 capex ₹376.22m.
• IPO proceeds deployed to PSEL and Palghar capex; liquidity for working capital.
• Rivadu Lifesciences subsidiary incorporated 18 Mar 2026.

Global footprint & exports

• Operations in 30+ countries; export share ~15%.
• Key markets include France, Germany, UK, Saudi Arabia, China, South Africa.
• Egypt facility expands access to MENA, Europe, Africa.
• Rivadu Lifesciences 100% owned as of 31 Mar 2026.

R&D & sustainability

• R&D team ~20 scientists across four labs; DSIR-recognised unit.
• NSF 533 certification; UniPack CPVC additive platform.
• Zero Liquid Discharge and green chemistry initiatives.
• CSR spend ₹1.16 crore; education, healthcare, environment.
• Earth Day garden; ~200 trees planted in 2026.

Governance & management

• CFO change: Ashok Bothra appointed Sep 6, 2025; Mittal resigned Jul 16, 2025.
• Six Board meetings in FY26; Independent Directors met Feb 12, 2026.
• Material subsidiary Platinum Stabilizers Egypt LLC; independent director not mandatory.
• CSR Committee; whistleblower policy; SEBI LODR compliance.

Dividend & IPO allocation

• Dividend not declared; profits retained.
• IPO proceeds: utilised ₹1,507.87m; unutilised ₹610.42m as of 31 Mar 2026.
• AGM approvals for related party transactions with Egyptian subsidiaries.
• Standalone audit flagged due to a fire loss; insurance claim pending.

Audit, risk & controls

• PKF Sridhar & Santhanam LLP; standalone qualified opinion due to fire claim.
• Insurance claim receivable from subsidiary pending; recovery expected.
• Internal controls robust; risk management framework in place.

AGM details

• 6th AGM scheduled for 24 September 2026 at 11:00 IST via VC/OAVM.
• Cut-off date for eligibility to vote is 17 September 2026.
• Remote e-voting window runs 21–23 September 2026 from 09:00 to 17:00 IST.
• Notice and Annual Report available electronically on the company's website.

Resolutions put to vote

• Ordinary: Adopt standalone financial statements for FY2025-26.
• Ordinary: Adopt consolidated financial statements for FY2025-26.
• Ordinary: Re-appoint Anup Singh as director by rotation.
• Ordinary: Ratify remuneration of Cost Auditor for FY2026-27 at ₹85,000.
• Special: Grant of loan/ICD to Platinum Oleo Chemicals Private Limited up to ₹25 crore at 9%.
• Special: Grant of loan/ICD to Rivadu Lifesciences Private Limited up to ₹25 crore at 9%.
• Ordinary: Material Related Party Transaction with Platinum Stabilizers Egypt LLC up to ₹800 million.
• Ordinary: Material Related Party Transaction with Platinum Oleo Chemicals Private Limited up to ₹800 million.

Directors & auditors

• Re-appointment of Mr. Anup Singh as director by rotation.
• Cost Auditor remuneration for FY2026-27 ratified at ₹85,000.

Related party transactions

• RPT with Platinum Stabilizers Egypt LLC up to ₹800 million for FY27.
• RPT with Platinum Oleo Chemicals Private Limited up to ₹800 million for FY27.

Voting status

• Voting results for all resolutions are not disclosed in the filing.